Boston Scientific signs agreement to divest BTG Specialty Pharmaceuticals business

This article was originally published here

SERB, backed by private equity firm Charterhouse Capital Partners since 2017, owns a diversified portfolio of prescription medicines focused on rare and life-threatening diseases. “This transaction will help

The post Boston Scientific signs agreement to divest BTG Specialty Pharmaceuticals business appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply